Why Is VIR BIOTECHNOLOGY IN (VIR) Stock Moving Today?
By the Top Tier Newswire AI Desk · October 8, 2026 at 10:23 AM ET · reviewed against 9 wire stories
VIR BIOTECHNOLOGY IN (VIR) is drawing unusual attention today. Our newswire has captured 9 stories on VIR across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Vir Biotechnology shares fell 5.64% to $10.87 on October 8, 2026. The decline followed the company’s announcement that the U.S. Food and Drug Administration granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for late-line metastatic castration-resistant prostate cancer. While the regulatory milestone supports a planned Phase 3 push in 2027, the stock retreated from recent highs despite positive analyst revisions.
What Happened
Vir Biotechnology filed an 8-K on October 8, 2026, disclosing the FDA Fast Track designation for VIR-5500. The company stated that this status sets up a 2027 Phase 3 trial in late-line prostate cancer. H.C. Wainwright raised its price target on the stock to $22 from $20, maintaining a Buy rating. The firm cited the regulatory progress as a key catalyst. Additionally, Vir Biotechnology appointed Liu as Chief Medical Officer and named Aziz Sawaf as Chief Financial Officer, effective October 5. The company also announced it will present expanded Phase 2 SOLSTICE results for elebsiran and tobevibart in hepatitis delta at AASLD’s The Liver Meeting 2026.
What The Data Shows
The stock opened at $11.50 and reached a session high of $12.00 at 8:30 AM ET before sliding to a low of $10.83 at 10:15 AM ET. Volume stood at 0.2 million shares, which is 0.1 times the 3-month daily average. The company has a market capitalization of $2.0 billion and is currently unprofitable, with a trailing twelve-month EPS of -$1.70. Revenue grew 1495.9% over the trailing twelve months, though the net margin remains at -83.0%. The stock has a beta of 1.59 and trades within a 52-week range of $4.82 to $11.94. Over the last eight sessions, the stock had moved up 9.6% from $10.51 to $11.52. On October 8, the tape printed one fresh 52-week high and eleven fresh 52-week lows.
What To Watch
Investors will monitor the upcoming presentation of expanded Phase 2 SOLSTICE results for elebsiran and tobevibart at AASLD’s The Liver Meeting 2026. The market will also track the progress of the 2027 Phase 3 trial for VIR-5500 in metastatic castration-resistant prostate cancer.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
VIR · today's session (5-min) · -5.47% vs prior close · updated 10:22 AM ETAI sentiment, last 36h · averaged over 9 stories · 63/100 bullish
The headlines behind the move
Story flow · 9 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoMarketChameleonBULLISH 67Product/PR
Vir Biotechnology says FDA Fast Track for VIR-5500 sets up a 2027 Phase 3 push in late-line prostate cancer
October 8, 2026
Vir Biotechnology said the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer. The company noted VIR-5500 is in a Phase 1 program spanning six dose-expansion cohorts and said pivotal Phase 3 trials are anticipated to begin in 2027.
6h agoTipRanksBULLISH 64Product/PR
Vir Biotechnology gains FDA Fast Track for VIR-5500
Vir Biotechnology ( ($VIR) ) has shared an announcement. On October 6, 2026, Vir Biotechnology announced that the U.S. Food and Drug Administration granted Fast Tra...
7h agoSEC 8-KNEUTRAL 50General
Vir Biotechnology, Inc. (VIR) files 8-K
Filed: 2026-10-08 AccNo: 0001628280-26-065408 Size: 242 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
7h agoThe FlyBULLISH 74Product/PR
Vir Biotechnology announces U.S. FDA granted FTD to VIR-5500
7h agoStockTitanBULLISH 74Product/PR
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
H.C. Wainwright raises Vir Biotechnology price target to $22
H.C. Wainwright raises Vir Biotechnology price target to $22
1d agoThe FlyBULLISH 61Analyst
Vir Biotechnology price target raised to $22 from $20 at H.C. Wainwright
1d agoThe FlyBULLISH 56General
Vir Biotechnology appoints Liu as Chief Medical Officer
1d agoStockTitanBULLISH 56Product/PR
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology appoints David Liu as EVP & chief medical officer, effective Oct 12, 2026.
Frequently asked questions
Why is VIR stock moving today?
VIR BIOTECHNOLOGY IN (VIR) is drawing unusual attention today. Our newswire has captured 9 stories on VIR across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "Vir Biotechnology says FDA Fast Track for VIR-5500 sets up a 2027 Phase 3 push in late-line prostate cancer
October 8, 2026" (MarketChameleon).
Is VIR a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of VIR coverage reads 63/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →